Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD16/IL-15/anti-CD33 trispecific natural Killer cell engager GTB-3650

A trispecific natural killer (NK) cell engager comprised of an anti-cluster of differentiation 16 (CD16; FcgammaRIII) camelid nanobody, human interleukin-15 (IL-15), and an anti-CD33 single-chain variable fragment (scFv), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD16/IL-15/anti-CD33 trispecific NK cell engager GTB-3650 targets and binds to CD33 expressed on tumor cells and simultaneously binds to the activating CD16 Fc receptor expressed on NK cells, thereby bringing CD33-expressing tumor cells and NK cells together. This induces NK cell cytotoxicity specifically against CD33-expressing tumor cells. The cytokine IL-15 promotes NK cell proliferation, activity, survival and expansion. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD16/IL-15/anti-CD33 trispecific killer engager GTB-3650
anti-CD16/IL-15/anti-CD33 trispecific NK cell engager GTB-3650
anti-CD16/IL-15/anti-CD33 trispecific NK engager GTB-3650
anti-CD16/IL15/anti-CD33 TriKE GTB-3650
Code name:GTB 3650
GTB-3650
GTB3650
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search